This briefing discusses the executive roundtable convened by Signal49 Research to look at ways to ensure affordable and sustainable access to innovative medicines for Canadians.
Document Highlights
Canada should develop the capacity to collect and analyze “real world evidence” on patient outcomes.
New and novel funding models should be explored, developed, and tested.
Creating a multi-stakeholder forum for ongoing discussions and collaboration will allow for consensus building on common goals and principles.
There are no reviews yet.